Medicaid coverage
West Virginia: what Medicaid covers
West Virginia has no weight-loss or anti-obesity class at all. It files the two drugs under the condition instead: Wegovy sits under major adverse cardiovascular event reduction and under metabolic dysfunction-associated steatohepatitis, Zepbound under obstructive sleep apnea, and each class carries its own prior authorization criteria. Saxenda is not named.
| Drug | Position | Criteria |
|---|---|---|
| Semaglutide | Other indications only | Wegovy appears only under the cardiovascular event reduction class and the MASH class, both with prior authorization criteria |
| Tirzepatide | Other indications only | Zepbound appears only under the obstructive sleep apnea class, with prior authorization criteria |
| Liraglutide | not checked | Saxenda is named nowhere on the preferred drug list, and the list has no weight-loss class |
-
Semaglutide Other indications only
Wegovy appears only under the cardiovascular event reduction class and the MASH class, both with prior authorization criteria
-
Tirzepatide Other indications only
Zepbound appears only under the obstructive sleep apnea class, with prior authorization criteria
-
Liraglutide not checked
Saxenda is named nowhere on the preferred drug list, and the list has no weight-loss class
Sources
Every claim above is checked against the primary text, and the date is the day we last opened it.
-
1
West Virginia Medicaid Preferred Drug List and Prior Authorization Criteria, effective April 1, 2026
West Virginia Bureau for Medical Services, Office of Pharmacy Services Primary text read and checked Checked August 28, 2026